Cholesterol Targets for Secondary Prevention: How Low Should LDL Go?

What Are the Current LDL Cholesterol Targets for Secondary Prevention?

Secondary prevention — reducing the risk of recurrent events in patients who already have atherosclerotic cardiovascular disease (ASCVD) — relies heavily on aggressive lipid lowering. The American College of Cardiology and American Heart Association (ACC/AHA) guidelines recommend high-intensity statin therapy for these patients, targeting LDL cholesterol reductions of 50% or more from baseline. The European Society of Cardiology (ESC) goes further, recommending an LDL goal below 55 mg/dL for very high-risk patients.

Despite these clear targets, a significant treatment gap persists. Studies consistently show that a substantial proportion of patients with established ASCVD do not achieve recommended LDL levels. Barriers include medication nonadherence, statin intolerance, underuse of add-on therapies like ezetimibe and PCSK9 inhibitors, and the cost of newer lipid-lowering agents. The role of drug manufacturer coupons in bridging cost barriers has become an increasingly discussed topic among clinicians and health policy experts.

Does Lowering LDL Below 55 mg/dL Provide Additional Cardiovascular Benefit?

The IMPROVE-IT trial, published in the New England Journal of Medicine in 2015, demonstrated that adding ezetimibe to statin therapy to achieve lower LDL levels (around 54 mg/dL versus 70 mg/dL) reduced cardiovascular events over seven years in post-acute coronary syndrome patients. The FOURIER trial, also published in the NEJM in 2017, showed that the PCSK9 inhibitor evolocumab reduced LDL to a median of 30 mg/dL and significantly lowered the risk of major cardiovascular events.

These findings have reinforced the 'lower is better' hypothesis for LDL cholesterol in secondary prevention. However, questions remain about the cost-effectiveness of achieving ultra-low LDL targets, particularly with expensive biologic therapies. Drug manufacturer coupon programs for PCSK9 inhibitors like evolocumab and alirocumab have helped some patients access these medications, though critics argue coupons can obscure true costs and complicate insurance formulary negotiations. Clinicians must weigh the cardiovascular benefits of aggressive LDL lowering against practical considerations of access, adherence, and long-term safety at very low lipid levels.

How Do Drug Manufacturer Coupons Affect Cholesterol Treatment Access?

Drug manufacturer coupons — also known as copay assistance programs — have become widespread for branded cardiovascular medications, including PCSK9 inhibitors and newer combination therapies. These programs can reduce patient copays to as little as zero dollars per month, removing a significant barrier to initiating and maintaining therapy. For patients with established ASCVD who need aggressive LDL lowering beyond what statins alone can achieve, such programs can be clinically meaningful.

However, health economists and pharmacy benefit managers have raised concerns. Coupons may steer patients toward expensive branded drugs when lower-cost alternatives exist, potentially increasing overall healthcare spending. They can also create a coverage cliff when patients lose coupon eligibility or when coupons expire, leading to abrupt discontinuation of therapy. The broader policy discussion touches on drug pricing transparency, formulary design, and whether short-term cost relief through coupons translates into sustained treatment adherence and improved cardiovascular outcomes over time.